Gilead Sciences, Inc. with ticker code (GILD) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $106.63 and $65.27 suggesting an average Analsyt target price of $82.55. Now with the previous closing price of $75.04 this would indicate that there is a potential upside of 10.0%. There is a 50 day moving average of $76.84 and the 200 day moving average is $78.86. The market capitalization for the company is 92.85B. The current share price for the company is: $74.52 USD
The potential market cap would be $102,147,817,495 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 15.96, revenue per share of $21.90 and a 9.21% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
